Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

<div>Cumulative overall survival rates and Kaplan–Meier analysis of subgroups. AFP&gt;400 ng/mL and portal vein invasion were the independent risk factors for overall survival by the log-rank test of multivariate analysis. Targeted therapy or immunotherapy was not the independent risk factor for overall survival.</div>

Canadian Journal of Gastroenterology and Hepatology

fig4

Figure 4

Figure 4: Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 

Figure 4 | Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 